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Abstract
While preclinical and clinical imaging have been applied to drug discovery/development and
characterization of disease pathology, few examples exist where imaging has been used to
evaluate infectious agents or countermeasures to biosafety level (BSL)3/4 threat agents.
Viruses engineered with reporter constructs, i.e., enzymes and receptors, which are amenable
to detection by positron emission tomography (PET), single photon emission tomography
(SPECT), or magnetic resonance imaging (MRI) have been used to evaluate the biodistribution
of viruses containing speciﬁc therapeutic or gene transfer payloads. Bioluminescence and
nuclear approaches involving engineered reporters, direct labeling of bacteria with radiotracers,
or tracking bacteria through their constitutively expressed thymidine kinase have been utilized to
characterize viral and bacterial pathogens post-infection. Most PET, SPECT, CT, or MRI
approaches have focused on evaluating host responses to the pathogens such as inﬂammation,
brain neurochemistry, and structural changes and on assessing the biodistribution of
radiolabeled drugs. Imaging has the potential when applied preclinically to the development of
countermeasures against BSL3/4 threat agents to address the following: (1) presence,
biodistribution, and time course of infection in the presence or absence of drug; (2) binding of
the therapeutic to the target; and (3) expression of a pharmacologic effect either related to drug
mechanism, efﬁcacy, or safety. Preclinical imaging could potentially provide real-time dynamic
tools to characterize the pathogen and animal model and for developing countermeasures under
the U.S. FDA Animal Rule provision with high conﬁdence of success and clinical beneﬁt.
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Introduction
Preclinical and clinical in vivo imaging approaches havebeen widely utilized in the characterization of disease
and drug efﬁcacy across numerous therapeutic areas, most
notably, neuroscience, oncology, cardiovascular, and immu-
nology. Few examples exist where in vivo imaging has been
applied to the evaluation of infectious agents, anti-infective
drug discovery, and/or biosafety level (BSL)3/4 biothreat
agents. There are very likely several practical reasons for the
limited use of in vivo imaging in the assessment of BSL3/4
infectious agents such as the need for signiﬁcant biocon-
tainment facilities of which there are few where imaging
capabilities exist, isolation of imaging hardware from
infected animals, and the rapid onset of the disease in
infected animals. Attempts to image animals infected with
BSL3 agents have employed self-contained isolation cham-
bers, i.e., sealed tubes [1, 2] to avoid contamination. Some
groups have installed imaging systems within a BSL2
environment to allow for easier hardware maintenance or
utilized large Philips Bioshield™ polycarbonate plastic tubes
extending from the BSL4 containment space into the bores
of the various scanners to isolate the hardware from the
infectious agents [3]. Others have installed the imaging
equipment directly into BSL3 containment and developed
procedures for infected animal isolation and hardware
decontamination, e.g., gaseous paraformaldehyde or hydro-
gen peroxide. All of the above approaches come with
various disadvantages such as the requirement for modiﬁed
imaging hardware to accommodate the containment barriers,
reduced image resolution, scatter and attenuation, reduced
ﬂexibility or higher cost of operation with regard to using
disposable components, e.g., magnetic resonance imaging
(MRI) surface coils, and the potential exists for a reduced
hardware lifespan due to exposure to caustic decontamina-
tion solvents. Animal isolation approaches and imaging
outside of containment limit the breadth of pathogens that
could be utilized due to safety concerns related to isolation
chamber malfunction, security risks associated with taking
infected animals outside containment, and risks of exposure
due to personnel errors.
Despite the challenges, in vivo imaging could play a
signiﬁcant role in better understanding the pathophysiology
of infectious agents and in the discovery and development of
therapies for BSL3/4 pathogens. Given the nature of the
pathogens and despite the absence of drugs to treat the
infections, classical methods of drug development cannot be
applied. The development pathway for anti-viral and anti-
bacterial products against viral and bacterial threat agents is
complex because clinical efﬁcacy studies may not be
feasible or ethical. In these instances, the U.S. FDA Animal
Rule allows animal efﬁcacy data to be used along with
human safety evaluation data and pharmacokinetic informa-
tion to support drug approval [4]. Under the Animal Rule, a
thorough understanding of the pathophysiology of the agent
in the animal is needed so as to qualify that the model used
for drug efﬁcacy assessment and for linkage to phase I
human pharmacokinetic/pharmacodynamic parameters is
representative of the human condition.
In vivo imaging is well suited to provide a dynamic
assessment of pathogen infection, disease progression, and
resolution following drug intervention. The in vivo imaging
tools are non-invasive except when using contrast agents,
e.g., MRI, computed tomography (CT), and ultrasound (US),
or semi-invasive, e.g., positron emission tomography (PET),
single photon emission computed tomography (SPECT), and
optical, and when used together can serially monitor both
structural and functional changes associated with disease
progression. In this article, we will review (1) our basic
understanding of viral and bacterial infections with an
emphasis on BSL3 and BSL4 agents; (2) the general
principles underlying the various imaging modalities; (3)
application of preclinical in vivo imaging in drug discovery;
and (4) the current approaches where in vivo imaging has
been applied to evaluate viral and bacterial pathogens and
drug/countermeasure interventions.
Processes Involved in Viral
and Bacterial Infections
Viral and bacterial infections involve a series of steps that
while not independent are pathogen and route of inoculation
speciﬁc such as cellular uptake, replication and spread of the
pathogen, and host speciﬁc such as modulation of the innate
and adaptive immune response to the infectious agent. To
identify the steps where in vivo imaging can play a role in
better understanding the pathogenesis of the infectious
agents, we will brieﬂy review the life cycle of a viral agent,
Venezuelan equine encephalitis virus (VEEV), and bacteria
agent, Burkholderia pseudomallei, which are potential
biothreat agents.
Alphaviruses are small, i.e., 65–70 nm, encapsulated
spherical particles containing a positive-strand genomic
RNA of approximately 11.5 kb in length. Alphaviruses
referred to as “old world” viruses such as Sindbis virus
(SINV), Semliki Forest virus, Ross River virus (RRV), and
Chikungunya (CHIKV) cause rheumatic diseases in humans
[5]. The “new world” viruses, Venezuelan, Eastern, and
Western equine encephalitis virus (VEEV, EEEV, WEEV),
cause fatal encephalitic diseases in the Americas [6]. The
general process of alphavirus infection (for review, see
references [7–10]) is depicted in Fig. 1. The alphavirus binds
to cell receptors mediated by the viral E2 glycoprotein and
internalized in a clathrin-dependent manner. Under low pH,
the nucleocapsid is released into the cytoplasm through a
fusion pore of viral and endosomal membranes where it
disassembles to expose the RNA for translation in cytoplas-
mic vacuoles. The viral replicase complex assembles upon
translation of the non-structural proteins with minus-strand
RNA synthesis occurring early and both plus-strand and
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subgenomic RNA synthesis occurring late in infection.
Genomic RNA is transcribed while structural proteins
involved in capsid formation are translated from subgenomic
RNA as a polyprotein of capsid-pE2-6K-E1. The
polyprotein inserts into the endoplasmic reticulum for
further processing while the genomic RNA and capsid are
assembled in the cytoplasm. Fusion of the newly synthesized
nucleocapsid and viral glycoproteins occurs at the cell
membrane and budding of new virus results. To mitigate
an immune response, alphavirus infection shuts down the
host transcription and translation processes without affecting
virus replication, decreases IFN-α/β production which
reduces the innate immune system and host anti-viral
responses, and promotes cytopathic responses responsible
for induction of the apoptotic pathway. In the cases of
alphavirus-induced encephalitis and articular disease/myal-
gia, the hallmark host response is macrophage inﬁltration,
cytokine and chemokine release, and edema.
B. pseudomallei is a gram-negative bacteria measuring
2–5 μm in length and 0.5–0.8 μm in diameter and which is
endemic to tropical areas in Southeast Asia and Northern
Australia. Infection with B. pseudomallei can occur via
percutaneous inoculation, inhalation, or aspiration, and the
sensitivity to infection and resulting melioidosis is depen-
dent on the individual’s immune status and presence of
underlying conditions such as diabetes, renal disease, and
alcohol abuse. The process of B. pseudomallei infection
(see reference [11, 12] for review) is diagrammatically
represented in Fig. 2. Following inhalation exposure, B.
pseudomallei binds to the pharyngeal epithelial cell presum-
ably through an asialoganglioside aGM1–aGM2 receptor
complex mediated by the bacterial type IVA pili. The method
of invasion of the bacteria into the cell is unknown, but the
event is associated with rearrangement of the host actin
cytoskeleton induced by the Burkholderia secretion apparatus
(Bsa) type 3 secretion system (T3SS). In epithelial cells, B.
pseudomallei represses inducible nitric oxide synthase (iNOS)
by activating expression of a suppressor of cytokine signaling 3
(SOCS3) and cytokine-inducible src homology 2-containing
protein (CIS). Upon phagocytic or non-phagocytic cellular
uptake, the bacteria appear in vacuoles and with the aid of
T3SS escapes into the cytoplasm where it replicates. In
macrophages, replication continues without activating a bacte-
ricidal response. Repression of the bactericidal response is
associated with a reduction in reactive oxygen or nitrogen
intermediates. In macrophages, B. pseudomallei represses
iNOS and interferon-β expression by activating sterile-α and
Armadillo motif (SARM) containing protein [13]. Bacterial
spread is accomplished through macrophage lysis and through
intracellular spread by membrane protrusions to nearby cells or
by cell fusion to produce multi-nucleated giant cells. B.
pseudomallei travel between cells by actin-mediated motility
involving BimA to form actin tails. Dissemination of the
bacteria within the host is likely accomplished through
macrophages or transport through the lymphatic system within
a polysaccharide and lipopolysaccharide capsule which pro-
tects the bacteria from complement-mediated killing and
provide resistance to cationic peptides, respectively [11]. The
acute host response to B. pseudomallei is a rapid inﬂux and
activation of neutrophils followed by macrophage inﬁltration
and stimulation of an immune response mediated through Toll-
like receptors (TLRs) 2 and 4 plus expression of the
proinﬂammatory cytokines IL-6, IL-10, IL-12, IL-15, IL-18,
TNFα, and IFNγ which contribute to the tissue destruction and
pathogenesis of melioidosis. The cellular immune response
requires the presence of macrophages and CD4+ T cells, and
Fig. 1 Diagrammatic representation of the process of alphavirus infection.
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anti-lipopolysaccharide antibodies appear to be a potential
mechanism for bactericidal activity.
Host pathogen interactions are complex and involve a
diverse range of mechanisms by which the pathogens can
cause disease. However, the cellular process of infection
typically involves common steps of binding, internalization,
replication, muted host anti-viral and anti-bacterial response,
budding, and distribution within the host to initiate disease.
Disease initiation and progression, irrespective of alphavirus
or B. pseudomallei infection, involves a pronounced inﬂam-
mation of brain, joints, or lung resulting in encephalitis,
arthralgia, or melioidosis, respectively. Beyond using optical
and nuclear approaches to demonstrate the distribution of a
modiﬁed pathogen containing a reporter construct, in vivo
imaging could provide dynamic, serial information about
disease progression following a viral and bacterial infection.
Given the relative paucity of information utilizing imaging
to study infectious agents, the subsequent sections will
review applicable imaging tools used in the evaluation of
disease processes of relevance to infectious agents, e.g.,
inﬂammation and neurologic disorders. In addition, the uses
of imaging in drug discovery will be highlighted and speciﬁc
applications of where imaging has been used to study
infectious agents will be summarized.
Imaging in Drug Discovery
and Development
Basic Principles of Imaging
Over the course of the last decade, imaging devices such as
optical (bioluminescent and ﬂuorescent), PET, SPECT, CT,
US, and MRI have been developed for use in preclinical
studies. Comparison of the resolution, sensitivity, and key
Fig. 2 Diagrammatic representation of Burkholderia pseudomallei infection.
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features of each imaging modality is summarized in Table 1.
Optical imaging is a measure of light emitted from a probe,
e.g., green ﬂuorescent protein and luciferase-luciferin, and
used primarily in nude or non-pigmented mice, as a reporter
of a speciﬁc cellular process or demonstration of the
distribution of a target or cell. PET is a nuclear approach
which detects two 511-keV photons emitted at 180° apart
from an annihilation reaction of a positron produced from
the decay of an unstable exogenously delivered tracer such
as ﬂuorine-18, carbon-11, and copper-64 coupled to a target
molecule of interest, e.g., 2-deoxy-2- [18F]ﬂuoro-D-glucose
([18F]-FDG), which is used to measure a speciﬁc enzymatic,
receptor, or protein interaction. When PET is coupled with
CT or MRI, the radiotracer reagents can be co-localized to
speciﬁc regions within organs with ﬁner precision. SPECT
imaging detects gamma-emitting isotopes, e.g., technetium-
99m (Tc-99m) and iodine-123 (I-123), conjugated to targets
of interest much like PET, and some isotopes can be used to
image molecules such as proteins and antibodies for longer
periods of time. CT is a three-dimensional measure of X-ray
attenuation properties of different tissues, and while lacking
in innate contrast sensitivity, it provides very high spatial
resolution, which is detector size and X-ray dose-dependent.
CT provides high-resolution structural images of bone and
lung and with the addition of contrast agents is somewhat
capable of soft tissue imaging. Ultrasound is a two-
dimensional measure of reﬂected high-frequency sound
waves from a tissue of interest to create a structural image
of the tissue in the transducer ﬁeld-of-view and can be used
in Doppler mode for perfusion with or without bubbles to
improve contrast resolution. MRI is a three-dimensional
measure of proton magnetization where image contrast is a
function of the tissue environment within which the proton
resides and can be interrogated with various techniques, e.g.,
bladder—may appear bright on a T2 sequence but dark on a
T1 sequence. MRI like CT has very high soft tissue contrast
resolution without the need for ionizing radiation. Taken
together, optical, PET, and SPECT while not exclusively are
best characterized as modalities amenable to molecular and
functional imaging and CT, US and MRI are best utilized for
anatomical imaging; however, some protocols with and
without contrast agents have been developed to measure
functional processes such as blood ﬂow.
Applications of Imaging in Drug Discovery
Coincident with the development of the preclinical imaging
tools, their application to the drug discovery and develop-
ment process has become more widespread. Imaging is well-
suited to evaluate (1) the presence of a therapeutic target or
drug at their speciﬁc site of action; (2) binding of the
therapeutic to the target; and (3) expression of a pharmaco-
logic effect either related to drug mechanism, efﬁcacy, or
safety. Applications of imaging for assessment of these three
processes can be found in neuroscience, oncology, cardio-
vascular, and immunology. Examples, while not exhaustive
with regard to what is available in the literature, are
highlighted below to demonstrate how imaging has been
applied to these disease areas to address the above three
questions and to exemplify by extension how imaging can
address processes of relevance to infectious diseases.
In neuroscience, the utilization of PET tracers has become
a somewhat standard method for demonstrating brain
receptor or enzyme expression and drug occupancy, while
MRI is utilized to quantify structural and/or functional
Table 1. Comparison of the imaging modalities
Imaging modality Resolution (μm) Sensitivity Key features
Optical 2,000 pM–fM Two-dimensional
Limited depth of penetration
Molecular and functional imaging
Mice (nude or non-pigmented) only
PET 1,500–2,000 nM–pM Three-dimensional
Short- and long-lived isotopes
Molecular and functional imaging
SPECT 100–200a nM–pM Three-dimensional
Potential for imaging multiple probes simultaneously
Molecular and functional imaging
CT 30+ μM Three-dimensional
Primarily bone and lung imaging
Soft tissue imaging requires contrast agents
Anatomical imaging
Ultrasound 30+ μM Two-dimensional
Depth of penetration dependent on transducer frequency
User dependent due to manual manipulation of transducers
Anatomical imaging
MRI 10+ μM Three-dimensional
No ionizing radiation
Anatomical imagingb
aResolution is scanner dependent
bPotential for functional imaging using contrast agents
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processes such as ﬂow, perfusion, diffusion, and neuronal
activation. There are numerous examples of the use of
imaging in the study of neuroscience, neuropathology, and
drug intervention [14–16]. Most recently, a novel phospho-
diesterase 2A (PDE2A) tracer, 4-(3-[18F]ﬂuoroazetidin-1-
yl)-7-methyl-5-{1-methyl-5-[4-(triﬂuoromethyl)phenyl]-1H-
pyrazol-4-yl}imidazo[5,1-f]-[1,2,4]triazine ([18F]PF-
05270430), was identiﬁed through a rational PET tracer
design methodology [17]. In cynomologus monkeys,
[18F]PF-05270430 was used to demonstrate the distribution
of PDE2A to brain striatum (putamen and caudate) and not
cerebellum and while not shown such binding was noted to
be blocked in a dose-dependent manner by a speciﬁc
PDE2A inhibitor [17]. When the tissue distribution, drug
binding to a speciﬁc target and PK data are taken together,
one can correlate plasma drug levels with the speciﬁc target
occupancy needed for drug efﬁcacy. Novel PET tracers have
been used to characterize the progression of disease such as
Alzheimer’s by quantifying the deposition of beta-amyloid
[18–20]. More general PET tracers such as [18F]-FDG can
be used to discern changes in brain metabolism and drug
effects related to both efﬁcacy and safety. Magnetic
resonance imaging and MR spectroscopy have been used
to further characterize Alzheimer’s disease pathology by
assessing changes in brain size [21] and neuroinﬂammation
by measuring myoinositol levels [21, 22].
Application of imaging to the diagnosis and assessment
of treatment in oncology has been long-standing.
Multimodality approaches (for review, see [23]) have been
used preclinically to characterize growth and metastasis of
xenograft tumors and orthotopic tumors because the tradi-
tional caliper measurements inconsistently follow functional
changes. Measures of tumor metabolism and proliferation
have employed 2-deoxy-2-[18F]ﬂuoro-D-glucose ([18F]FDG)
and [18F]ﬂuoro-3-dexoythymidine ([18F]FLT) PET, respec-
tively. Staging the degree of tumor proliferation with
[18F]FLT has provided more consistent cohorts of animals
for drug testing, reduced variability in the measurement, and
demonstrated a pharmacologic effect prior to tumor size
changes [24, 25]. Dynamic contrast-enhanced MRI
(dceMRI) is routinely used to characterize tumor angiogen-
esis and changes in blood ﬂow following treatment [26].
From a preclinical perspective, optical imaging of tumors
containing ﬂuorescent or bioluminescent reporter constructs
has enabled rapid compound testing and staging of tumor
growth prior to applying the more complex PET, SPECT, or
MRI approaches. In addition to assessing drug mechanism
or efﬁcacy, imaging has been used to phenotype tumors,
e.g., expression of carcinoembryonic antigen [27], to better
deﬁne the appropriate course of clinical treatment and to
select potentially more responsive patient cohorts.
Cardiovascular imaging has focused primarily in the
areas of atherosclerosis and diabetes to characterize disease
progression and disease-modifying therapies. [18F]FDG is
used as a marker of vascular inﬂammation because macro-
phages resident within the atherosclerotic lesion exhibit an
increased metabolic activity [28, 29]. Treatment with
simvastatin reduces macrophage accumulation within human
atherosclerotic plaques and decreases [18F]FDG activity
consistent with such ﬁndings [30]. In diabetes, to quantify
the mass of pancreatic β-islet cells, a novel tracer,
[11C]dihydrotetrabenazine, which targets β-cell vesicular
monoamine transporter type II (VMAT2) has been shown
to detect pancreatic β-islet cells and reduction in cell mass in
streptozotocin-treated and Zucker rat models of diabetes [31]
and in human type I diabetics [32].
Immunological responses such as with inﬂammation are
present across multiple disease areas, and applications for
imaging can be found in rheumatoid arthritis [33] and
atherosclerosis [28–30] as noted above and infection and
general inﬂammation [34]. In general, [18F]FDG has been
used substantially to assess inﬂammation. More selective
markers for the peripheral-type benzodiazepine receptor
(PBR) or what is also referred to as the 18-kDa translocator
protein (TSPO), R-[11C]PK11195, can be used to more
directly demonstrate the presence of macrophages within the
area of inﬂammation. For infectious diseases, imaging has
been used to monitor the pathogen through direct labeling of
the pathogen (a more detailed description is below) and
assessment of the host response through monitoring inﬂam-
matory mediators and cellular and vascular responses [33].
For example, general markers of inﬂammation like
[18F]FDG, more selective cellular markers involving direct
labeling of neutrophils with a copper-64- or Tc-99m-labeled
peptides which bind to the formyl peptide receptor [35–37]
or direct labeling of monocyte/macrophages with In-111, R-
[11C]PK11195, or tracers of matrix degradation, i.e., matrix
metalloproteinases (MMPs), and tools for assessment of host
responses involved in transcriptional regulation, i.e., NF-κB,
and apoptosis, e.g., Tc-99m-labeled annexin V, have been
used [38]. The combination of imaging methodologies
provides a more thorough understanding of the molecular,
cellular, tissue, and organ response to a pathogen or insult
that result in an inﬂammatory response.
Individual and multi-modality imaging approaches can be
used to better characterize infections caused by biothreat
agents, assess the time course of infection and host response,
and evaluate drug distribution, drug targeting, and drug
efﬁcacy. Table 2 summarizes the types of physiologic
responses and imaging methods used to evaluate the
pathophysiology of disease in numerous therapeutic areas
and in drug discovery and development that are equally
amenable for studying infectious agents. Development of
new reporter constructs containing receptor or enzyme
reporters in BSL3/4 agents would be beneﬁcial to charac-
terize the distribution and time course of infection within
both rodent and non-rodent models using PET and SPECT
imaging. Direct labeling of known and novel drugs with
PET and SPECT radiotracers serves not only to demonstrate
drug biodistribution but also to link plasma and tissue drug
levels with pathogen load. Measures of tissue function,
metabolism, and activation, i.e., [18F]FDG-PET, magnetic
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resonance spectroscopy (MRS), ASL-MRI, and BOLD-
MRI, cell markers, i.e., [18F]FEDAC and inﬂammation,
changes in changes in cell phenotype and apoptosis, i.e., Tc-
99m-labeled annexin V, and measures of organ/tissue
structure i.e., MRI, CT, and ultrasound, all provide tools to
dynamically evaluate the host response to the BSL3/4 agent.
Based on a review of the literature, imaging has
demonstrable advantages over classical methods used for
the discovery and development of drugs. Besides reducing
the number of animals used in a study, in vivo imaging
allows one to perform whole body scans, dynamically, with
higher statistical power given that each animal can act as its
own control and with greater ﬂexibility than classical
methods such as histology. Histology is a sensitive measure
of disease pathology at a single time point. When imaging is
coupled with histology, imaging can be used to dynamically
measure disease progression and select cohorts of animals
with a similar state of disease for histologic assessment or
drug intervention. Imaging approaches as noted in this
section have been successfully utilized to characterize a
compound’s mechanism of action; to provide a proof of
concept or mechanism that a new drug entity engages their
Table 2. Applications of imaging for the assessment of disease pathophysiology and drug intervention
Imaging modality
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respective target; to demonstrate a pharmacologic effect
that can provide patient beneﬁt; or to deﬁne a drug dose
range which is linked to target engagement and where
side effects are limited or mitigated. Similar types of
questions also exist in the development of countermea-
sures against high consequence pathogens such as
biothreat agents, and application of imaging approaches
can provide conﬁdence in the animal model, drug
mechanism/target, or drug pharmacodynamics and aid
drug development.
Imaging Applications for Viruses
and Bacteria
Imaging applications can be divided into the evaluation of
the pathogen speciﬁcally and the host response to the
pathogen. While all imaging modalities have the potential
to assess the pathogen directly, optical and nuclear imaging
are typically used because of their inherent sensitivity.
Nuclear, MRI, and CT imaging are well suited for
assessment of the host response to the pathogen, e.g.,
morphological changes, organ metabolism, inﬂammation,
and hemodynamics. In the subsequent sections, each
approach will be reviewed and divided on the basis of
pathogen and host approaches where applicable.
Viral and Bacterial Reporter Constructs
Viruses engineered with reporter constructs such as enzymes
and receptors are amenable to detection by imaging and
used to evaluate the biodistribution of viruses containing
speciﬁc therapeutic or gene transfer payloads. Similarly
engineered BSL3/4 viruses can be used to study the virus
itself. Numerous reporter constructs have been developed
that are detectable by optical, PET, or SPECT imaging.
The most often used reporter is herpes simplex virus
thymidine kinase (HSV-tk1) with either [124I/18F]-29-
ﬂuoro-29-deoxy-1-b-D-arabinofuranosyl-5-iodouracil ([124I/
18F]FIAU) or 9-(4-[18F]ﬂuoro-3-(hydroxymethyl)butyl]guanine
([18F]-FHBG) as the enzyme substrate and PET as the imaging
modality [39–52]. The viral thymidine kinase is translated in the
cell along with the viral RNA and phosphorylates the
exogenously delivered radiolabeled [124I/18F]FIAU or
[18F]FHBG substrate, trapping it in cells and thereby labeling
cells which have been infected with the virus. Alternative
reporter enzymes such as human mitochondrial thymidine
kinase 2 (hmtk2) [43] and human deoxycytidine kinase
(hdCK) [43] utilizing 2′-deoxy-2-[18F]ﬂuoro-5-methyl-1-β-L-
arabinofuranosyluracil ([18F]-FMAU) and 2′-deoxy-2′-
[18F]ﬂuoroarabinofuranosylcytosine as substrates, respectively,
have been developed to avoid immunologic reactions in
humans. The varicella zoster virus thymidine kinase (VZV-tk)
in combination with radiolabeled bicyclic nucleoside analogs
as enzyme substrates is currently being evaluated as a
potential reporter construct [45].
Several receptor-based reporter systems such as the rat/
human sodium iodide symporter (NIS) [46–48], human
norepinephrine transporter (hNET) [49], human somatostatin
receptor (hSSTR2) [50], and rat dopamine D2 receptor
(D2R) [51] have been incorporated into viruses. Radio-
tracers amenable for PET or SPECT are available to quantify
expression of the different receptors following viral infec-
tion. The NIS reporter system is attractive because I-123, I-
124, I-131, and Tc-99m pertechnetate can be used which
obviates the need for complex chemistry [51]. The hNET
reporter system has the advantage of being easily incorpo-
rated into the virus because of the small size of the gene
cassette [52]. The radiotracers used for detection of hNET
are iodine-123, iodine-131, and meta-[123/124I]iodobenzyl-
guanidine. While hSSTR2 tracers such as [68Ga]DOTA-
TOC, [68Ga]DOTATATE, and [111In]DOTABASS provide
high speciﬁc binding and low background due to their rapid
clearance, the fact that DOTATOC and DOTATATE are
agonists for the G protein-coupled receptor, they can perturb
cellular function and confound the interpretation of the
results. Incorporation of the D2R into a virus and imaging
receptor expression with [18F]-ﬂuromethyl-spiperone has
been utilized; however, the use of a mutant (D2R80A)
proved more valuable because it completely uncoupled
ligand binding with activation of G protein-linked signaling
and adverse effects on the transduced cells [51]. Similar
receptor-based systems can be constructed with an MRI
detectable reporter, e.g., transferrin receptor and iron
accumulation [53, 54]. Despite signiﬁcant spatial resolution,
such MRI-based approaches lack the sensitivity of nuclear
and optical approaches and present potential artifacts due to
the longevity of the signal that may be associated with
remnants of cells containing the iron particles. With regard
to creating reporter systems in bacteria, less work has been
done.
While reporter systems have been developed to track
therapeutic genes associated with gene therapy, or stem cells
to assess viability and longevity or to act as radiolabeled
suicide molecules for oncolytic therapy, the procedures
developed for insertion of such reporters and evaluation of
their functionality can also be applied to studying the virus
or bacterial particle itself. Optical imaging and viruses/
bacteria containing reporter constructs such as luciferase/
luciferin or green ﬂuorescent protein which are amenable to
optical imaging have been utilized to evaluate pathogens and
are reviewed in the next section.
Optical Imaging
Bioluminescence approaches have been utilized to charac-
terize the biodistribution of viral and bacterial pathogens
post-infection. Luciferase which requires exogenous lucifer-
in administration or the lux operon containing both
luciferase and luciferin has been transfected into murid
herpesvirus-4 [55], varicella zoster [56], Venezuelan equine
encephalitis [57], Chikungunya [58], cowpox [59], and
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murine cytomegalovirus [60] viruses and bacteria such as
Staphylococcus aureus [61], enteropathogenic Escherichia
coli, and enterohemorrhagic E. coli [62], Bacillus anthracis
[63], Yersinia pestis [64–66], Francisella tularensis [67],
and Burkholderia mallei and pseudomallei [68, 69]. Incor-
poration of the optical reporter in the virus/bacteria noted
above was shown to not markedly affect growth rate,
survival, and infectivity and functioned similarly to the
wild-type pathogen. Factors inﬂuencing the expression of
the bioreporter were the choice of promoter, size of the
amino acid ﬂanking regions, and whether the construct was
inserted randomly or site-speciﬁcally. The bioreporters
allowed for whole body detection of pathogens, and
assessment of the time course of infection and the
bioluminescent signal was highly sensitive with the signal
intensity correlating to pathogen number.
Site-directed insertion of the luciferase construct is
important in preserving viral function, and when coupled
with the constitutive native promoters for speciﬁc viral
proteins, optical imaging can be used to assess early and late
stage viral replication. Insertion of the luciferase expression
cassette in murid herpesvirus-4 between open reading frames
open reading frames (ORF) 57 and 58 which are involved in
lytic replication and viral spread allowed for the monitoring of
virus distribution and function by bioluminescence [55]. The
addition of the bioreporter was shown to not markedly affect
viral functions. In varicella zoster virus, placement of click
beetle luciferase in-frame with ORFs 63, 68, and 70 and under
their constitutive promoters not only allowed for optical
imaging of the virus but also monitoring of IE63 and gE
luciferase fusion proteins which are involved in early and late
varicella replication, respectively [56]. These two studies
demonstrate that placement of the reporter constructs can
provide more than just virus location but also information
about the functioning of the virus and the role of speciﬁc viral
proteins in replication and intercellular infection.
Viral luciferase expression in combination with whole
body optical imaging has been used to characterize different
routes of viral infection and drug efﬁcacy. Intranasal
infection with murid herpesvirus-4 resulted in nasal and
lung expression of luciferase activity and abdominal organ
expression following intraperitoneal infection, while no
signal was detected following oral administration [55].
Intranasal infection with VEEV containing a luciferase
bioreporter demonstrated brain uptake of the virus 3 days
prior to clinical signs [57]. Chikungunya virus with a
luciferase reporter injected into the mouse footpad resulted
in local bioluminescence but not systemic signal [58].
Treatment of varicella virus-infected mice with valacyclovir
[56] and VEEV-infected mice with Ampligen, a TLR-3
agonist [57], resulted in a decrease in luciferase luminescence
which is suggestive of a reduction in viral replication. It is
interesting to note that optical imaging was also able to detect
upon withdrawal of valacyclovir that the luminescence signal
reappeared, reﬂecting renewed viral replication. Cidofovir
treatment at doses of 25 and 100 mg/kg administered
intraperitoneal (i.p.) to mice infected with a green ﬂuorescent
protein (GFP)-expressing cowpox virus signiﬁcantly reduced
the bioluminescent signal which is indicative of reduced viral
replication when the animals were imaged post-mortem [59].
In mice infected with a GFP-expressing mouse cytomegalovi-
rus (GFP-MCMV), i.p. administration of 100 mg/kg and
subcutaneous (s.c.) administration of 50 mg/kg ganciclovir
decreased the ﬂuorescent signal [60]. Treatment of GFP-
MCMV mice with 50 mg/kg, s.c., of a novel compound
identiﬁed by screening, 1-(3,5-dichloro-4-pyridyl) piperidine-
4-carboxamide (DPPC), delayed the appearance of a muted
ﬂuorescent signal [60]. These data taken together indicate that
optical imaging is a sensitive tool capable of characterizing
virus distribution, the effect of drug intervention and discerning
differences between dose and route of drug administration.
Dynamic, real-time optical imaging of bacteria transfected
with various bioluminescent reporters has exposed pathways of
infection which were previously undetected. Construction of B.
anthracis containing the lux operon established that following
inhalation and cutaneous infections, the B. anthracis spores
germinated at the site of inoculation while Peyer’s patches were
the main site of bacterial growth following intragastric
inoculation [63]. Contrary to our current understanding, optical
imaging established that B. anthracis germination occurred at
the site of inoculation and initially did not require transport to
the draining lymph nodes for propagation, but eventually all
routes of infection progressed to the lymph nodes. Following
intranasal B. mallei infection, a strong luminescent signal was
observed in the lung that could be reduced by intraperitoneal
administration of levoﬂoxacin, 24 h post-infection [68].
Similarly, intranasalB. pseudomallei exhibited a similar pattern
of infection but in addition optical imaging demonstrated that
the olfactory nerve was the route of entry for the bacteria into
the brain, and such entry occurred prior to bacteria being
detected in the blood [69]. Y. pestis which is a gram-negative
bacterium capable of causing bubonic, septicemic, and
pneumonic plague has been evaluated utilizing optical imaging
approaches to track both level and distribution of infection and
the effect of pharmacologic intervention [64–66]. Insertion of
the luxCDABE operon driven by either the PtolC or PcysZK
promoter into Y. pestis provided a tool to evaluate differing
routes of administration, i.e., intradermal, subcutaneous, or
intranasal. With the intradermal and subcutaneous routes,
bioluminescence from the LuxPcysZK strain was detectable
in the draining lymph nodes followed by systemic dissemina-
tion while intranasal exposure localized the signal to the lungs
and thoracic cavity [64]. Utilization of a non-disseminating
LuxPcysZK Δpla construct demonstrated that the biolumines-
cent signal was conﬁned to the site of inoculation as expected.
Some investigators [65] have also shown that bioluminescence
signal from Y. pestis CO92 pLux is capable of detecting 104
−105 cfu and is linearly correlated with the degree of infection.
Unlike excising the organs and counting colonies, the optical
imaging approach monitored the fairly variable progression of
infection in each animal, staging the degree of infection for
treatment group selection and thereby reducing the variability
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in the measurement. Levoﬂoxacin treatment (10 mg/kg/day for
6 days, 24 h after infection) signiﬁcantly reduced the
luminescent signal indicating that the treatment killed the
bacteria [66]. Thus, for B. anthracis, B. mallei, B.
pseudomallei, and Y. pestis, optical imaging was a powerful
tool to track the course of infection, deﬁne new pathways of
infection, and sensitive enough to discern changes due to drug
treatment.
Beyond using optical imaging to assess the degree and
localization of bacterial infections, it can also be coupled
with other optical reporters to better understand the
pathophysiology of the disease and consequences of drug
intervention. For example, in a skin wound model, a
bioluminescent S. aureus strain (SH1000) was used to track
the course of wound infection [61]. Performing the same
experiment in LysEGFP mice, which possesses green
ﬂuorescent neutrophils, one was able to assess both bacterial
infection and degree of inﬂammation as assessed by
neutrophil inﬁltration using bioluminescence and ﬂuorescent
optical imaging. Optical imaging has also proved viable for
the assessment of vancomycin–rifampin efﬁcacy against S.
aureus-induced prosthetic joint infection in mice [70].
Improvements in optical reagents are ongoing to both
increase the sensitivity of optical imaging and to be able to
image deeper organ structures. Incorporation of a red-shifted
derivative of ﬁreﬂy luciferase (FFlucRT) into Mycobacteri-
um tuberculosis [71] or use of a near-infrared ﬂuorogenic
substrate against the endogenous M. tuberculosis β-
lactamase [72] increased sensitivity to detect 104 and 102
colony-forming units, respectively. The red-shifted and near-
infrared agents also increased the depth from which the
optical signal can be detected. Targeting speciﬁc bacterial
transport pathways or secreted enzymes has also proved
viable for use in detecting infection. For example, ﬂuores-
cent dye-conjugated maltodextrin-based imaging probes are
internalized in bacteria expressing the speciﬁc transporter
and can be used for detection of these bacteria [73]. Probes
which are normally silent but ﬂuoresce when activated by
secreted nucleases have been used to demonstrate the
distribution of S. aureus in infected animals [74]. Thus,
generation of general and targeted reagents is another
mechanism to improve the utility and sensitivity of optical
imaging.
Optical imaging while limited to mouse models of
infection has established the utility of imaging to better
understand viral and bacterial infections, routes of infection,
and the effect of drug intervention. Based on what has been
learned through optical imaging, one would expect that
similar tools could be built for use in nuclear imaging, i.e.,
PET and SPECT. The methods employed to build the tools
for optical imaging can be instructive in building the
pathogen constructs amenable to nuclear imaging. The
nuclear imaging tools broaden applicability from rodents to
primates due to the ability of imaging deeper organs and as
such expand the number of animal models within which to
evaluate viral/bacterial distribution and pathophysiology.
The opportunity to evaluate viral/bacterial pathogens in
non-rodent models also provides a mechanism to evaluate
drugs for the treatment of BSL3/4 agents in models which
might be more predictive of the human condition and aid in
the registration of new drug applications under the U.S.
FDA Animal Rule.
Nuclear Imaging
Despite the amount of work performed with optical imaging
to develop transduced viruses as tools to monitor gene
therapy, oncolytic therapy, and stem cell survival [39–54], a
minimal amount of work has been done to develop tools
amenable to nuclear imaging to directly characterize viral/
bacterial distribution. A few examples utilizing bacteria have
been reported. Direct labeling of an attenuated Salmonella
abortusovis with technetium-99m was performed and eval-
uated in sheep [75]. Labeling efﬁciency was low, i.e., 30 %,
but bacterial viability was unchanged and the investigators
were able to discern the spatial and temporal patterns of
bacteria dissemination in the lymphatic system following a
sub-cutaneous injection. Several other investigators utilizing
Tc-99m or indium-111 (In-111) directly labeled Pseudomo-
nas aeruginosa, E. coli, Streptococcus, and S. aureus to
perform similar types of experiments [76–81]. While
labeling the pathogen directly appears to be a viable
approach, only acute evaluation is possible given that with
bacterial replication the signal is diluted and the potential for
freely circulating radiolabel can confound the results.
Several studies utilized the constitutively expressed bacte-
rial thymidine kinase (TK) or transfected TK and the
substrate, 1-(29deoxy-29-ﬂuoro-b-Darabinofuranosyl)-5-
[125I]iodouracil ([125I]FIAU), which is amenable to SPECT
imaging to monitor bacterial infections. Constitutively
expressed bacterial TK in E. coli, Enterococcus faecalis
49532, Staphylococcus pneumonia 49619, Staphylococcus
aureus 29213 and 25293, Staphylococcus epidermidis
F362 were successfully imaged by SPECT using
[125I]FIAU to demonstrate distribution post-infection [82].
Others have also shown that the [125I]FIAU signal is
strongly correlated with bacterial E. coli load with a limit
of detection of 109 colony-forming units/ml [83]. In
bacteria not expressing TK, incorporation of bacterial TK
into M. tuberculosis under the HSP60 promoter generated
a tool (M. tuberculosis Phsp60 TK) for use in assessing
infection associated with tuberculosis [84]. As with the
other studies noted above, SPECT imaging utilizing
[125I]FIAU was used to assess the degree of bacterial
infection and localization of the bacteria in the lung.
A few studies employing nuclear imaging approaches have
focused on studying the pathophysiology of infection and the
distribution of therapeutics designed to treat the infection.
Neuroinﬂammation related to exposure to herpes simplex virus
1 (HSV-1) was assessed by PET by quantifying β-glucuron-
idase secretion from activated microglia and by direct labeling
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of activated microglia using a marker for the PBR [85]. To
measure β-glucuronidase activity, a PET tracer, 1-O-(4-(2-
[18F]ﬂuoroethyl-carbamoyloxymethyl)-2-nitrophenyl)-O-β-D-
glucopyronuronate ([18F]FEAnGA), which acts as a substrate
for the enzyme was synthesized. Upon cleavage of
[18F]FEAnGA by β-glucuronidase, [18F]ﬂuoroethylamine is
released and because it is slowly cleared from tissue demon-
strates areas of increased enzyme activity associated with areas
of neuroinﬂammation. While there was not a one-for-one
correspondence between R-[11C]PK11195 and [18F]FEAnGA
as had been expected, the investigators demonstrated that there
was a relationship between tracer binding and the symptom
score which implies that PET imaging was able to more
objectively stage the level of neuroinﬂammation associated
with HSV-1 infection and thereby more accurately select
cohorts for comparison [85]. Lung inﬂammation associated
with exposure to the pandemic inﬂuenza virus (H1N1pdm)
[86] and M. tuberculosis [87] was assessed using PET and the
glucose analog, [18F]FDG. The investigators correlated the
increase in glucose metabolism with viral titers. Like with
neuroinﬂammation, direct measures of the 18-kDa translocator
protein or PBR have been performed following a lung
lipopolysaccharide challenge utilizing another selective ligand,
N-benzyl-N-methyl-2-[7,8-dihydro-7-(2-18F]ﬂuoroethyl)-8-
oxo-2-phenyl-9H-purin-9-yl]acetamide ([18F]FEDAC) [88].
[18F]FEDAC binding increased with the severity of lung
inﬂammation and primarily localized to neutrophils and
macrophages. A new SPECT tracer, [125I]Iodo-N,N-diethyl-
2-]2-(4-methoxy-phenyl)-5,7-dimethyl-pyrazolo[1,5-a]
pyrimidin-3-yl]-acetamide ([125I]DPA713), has been devel-
oped and demonstrated to have higher signal-to-noise ratios
than R-[11C] PK11195 and lower lipophilicity [89, 90].
Measures of tissue hypoxia utilizing [64Cu]Copper-diacetyl-
bis(N4-methyl-thiosemicarbazone (which is [64Cu]ATSM)
have demonstrated that M. tuberculosis-induced tuberculosis
lesions in mice are hypoxic and sensitive to varying drug
regimens [91]. While these nuclear imaging approaches do
not directly measure the degree of infection, they are
informative with regards to characterizing the host response
to the virus which can be used to identify treatment and
potentially new drug discovery approaches.
Evaluation of radiolabeled drugs as tools for nuclear
imaging is a new approach to characterizing infection as
well as evaluating the pharmacokinetics of the therapeutic.
Isoniazid (INH) is routinely used to treat tuberculosis.
Utilization of 2-[18F]ﬂuoroisonicotinic acid hydrazide (2-
[18F]INH) and evaluation in M. tuberculosis-infected ani-
mals demonstrated that 2-[18F]INH accumulates in the lung
at sites of infection and becomes associated with the
mycobacterium such that the radiolabel can be a direct
marker of M. tuberculosis [92]. In addition to demonstrating
drug exposure and pathogen presence, target-speciﬁc com-
pounds amenable to radiolabeling and PET or SPECT
imaging can be used to study various processes associated
with infection. For example, in a review by Bray and
colleagues [93], they hypothesized that radiolabeled
compounds can be used to demonstrate that targeted
therapeutics bind to the viral envelope glycoprotein, NS3
protease, RNA replication complex, or cell surface E1-E2
protein. Some therapeutic agents exist [93, 94] but little
work has been done to radiolabel the molecules and use
them as tools to better understand the processes involved in
infection and virus/bacteria replication. In addition to small
molecules, there are opportunities to radiolabel biologics
such as antibodies, mini-bodies, and diabodies as has been
demonstrated in the cancer ﬁeld [95–97]. Based on targeted
screening, tools that are more selective for speciﬁc viral and
bacterial processes could be generated.
Magnetic Resonance Imaging
A few papers have been published describing the use of MRI
in the evaluation of viral and bacterial infections to most
notably assess bacterial distribution [97] and germination/
proliferation [98]. S. aureus was labeled with iron oxide
nanoparticles which remained on the bacterial surface [97].
The labeling of the bacteria had no effect on growth and
ability to infect human umbilical vein endothelial cells in
vitro [97]. Upon infection, MRI was able to detect S.
aureus up to ﬁve cycles of cell division and with a
minimum detection limit of 105 bacteria colony-forming
units. In addition, upon macrophage phagocytosis of the
labeled bacteria, MRI detected the resulting inﬂammation
associated with infection. Chemical exchange saturation
transfer (CEST) MRI, albeit challenging to implement, has
recently been used to show that endogenous bacterial
contrast can be used to monitor the germination and
proliferation of bacteria [98].
Magnetic resonance imaging has also proved useful in
evaluating the host response to infection by measuring
inﬂammation [99], brain neurochemical changes [100], and
lung pathology [101]. Investigators have employed ﬂuorine-
19 (F-19) perﬂuorocarbon emulsions as a means of assessing
macrophage inﬁltration following S. aureus infection since
the macrophage phagocytosis the F-19 emulsions and F-19
can be detected by MRS [99]. The 19F MRS signal was
detected as early as 48 h post-infection and out to 9 days
post-infection [102]. Mice infected with S. aureus Xen29
containing the optical reporter luxABCDE operon induced a
thigh abscess, and following 30 mg/kg/day vancomycin or
15 mg/kg/day of linezolid for 7 days, a reduction in both F-
19 signal by MRS and bioluminescent signal was observed
indicating both a decrease in inﬂammation and infection,
respectively [102]. MRS has been applied to simian
immunodeﬁciency virus (SIM)-infected rhesus macaques to
study the acute effects of virus on brain neurochemistry,
reﬂective of changes in neuronal health [100]. While the
changes noted were brain region speciﬁc, focusing on the
frontal cortex reductions in N-acetyl aspartate, a measure of
neurodegeneration, increases in choline and myoinositol,
measures of gliosis, and no change in creatinine and
glutamate/glutamine were noted at 2 weeks post-infection
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that resolved by 4 weeks [100]. The changes were highly
correlated with the level of viremia and demonstrated that
MRS is capable of detecting subtle changes consistent with
neurodegeneration/neuroinﬂammation post-SIM infection.
1H-MRI and 3He diffusion MRI have proven to be useful
tools in evaluating lung architecture following Sendai virus
infection [101]. Given that 3He does not diffuse across the
alveolar wall, it is very sensitive to deﬁning and quantifying
small microstructural changes and combined with 1H MRI
establishing that airspace enlargement developed following
virus infection [101].
In vivo imaging taken in its entirety has proven to be a
sensitive tool for monitoring the distribution of engineered
viruses and bacteria by either optical or nuclear imaging
approaches and for assessing the consequences of infection.
In addition to characterizing disease progression, imaging is
a sensitive tool for assessing the degree of viral and bacterial
infections relative to plasma titers and for monitoring the
effects of drugs on pathogen growth and progression of
disease. Despite the amount of work done in the area of
optical imaging, opportunities exist to employ nuclear and
MRI imaging approaches to perform similar types of studies
in non-rodent models and also apply the tools to the
development of new drugs by correlating drug distribution
and levels with pathogen expression, by linking drug
exposure with pharmacologic effect and by establishing
predictive preclinical models of drug efﬁcacy that can serve
as a surrogate for phase II/III clinical studies given the
issues with development of countermeasures for BSL3/4
biothreat agents.
Conclusions
The pathogenesis of viral and bacterial infections involves
pathogen-speciﬁc activities such as binding, internalization,
replication, muted host anti-viral or anti-bacterial response,
and budding and host-speciﬁc responses that result in
disease. Drug discovery efforts could focus on eliminating
the pathogen or on treating or preventing the resulting
disease, of which the latter could also have broader
application in improving human health. In vivo imaging
can be directly applied to better understand the above
processes associated with the natural history of infectious
agents, the host response, and the discovery and develop-
ment of drugs for the treatment of infections caused by
BSL3 and BSL4 threat agents.
Classical approaches to the study of BSL3/4 infections
involve serial necropsies, tissue dissection, plaque counts,
and immunohistochemistry to demonstrate the distribution
of pathogens and degree of infection, drug extraction from
tissues as a measure of drug exposure, and mortality as
endpoints for assessing drug efﬁcacy. However, numerous
other questions requiring a dynamic assessment of infection
and pathophysiology remain unanswered. In addition to
knowing that an animal has been exposed to an aerosolized
dose of a pathogen, one needs to determine the dose of
pathogen received within the lung and the relationship of
breathing kinetics to dose. Since distribution of the pathogen
in the tissues and organs may differ acutely post-infection
versus late in infection, it is important to map the differences
so as to insure proper drug exposure late in infection. While
the degree of viremia or bacteremia and plasma drug levels
may be good measures to demonstrate infection and the
potential for drug efﬁcacy, respectively, correlating mea-
sures of tissue pathogen and tissue drug concentrations may
be more important to link efﬁcacy with drug dose. In some
instances like with VEEV, one must know both the time
course and route of brain infection and whether the
therapeutic agent under development reaches the brain in
sufﬁcient quantities to result in a beneﬁcial effect. In all
cases noted above, dynamic real-time measurements can
provide important data to track infection, host response, and
time course for intervention and to assess drug efﬁcacy
rather than rely on mortality as the sole endpoint. By using
dynamic measures of drug efﬁcacy, one might be better able
to discern potential mechanisms for efﬁcacy and potential
targets/target organs to reﬁne the drug discovery approach
and/or compound.
In summary, in vivo imaging can provide real-time, in-life
measures of (1) target distribution and drug exposure, (2)
binding of drug to the target, and (3) physiologic or
pharmacologic consequences of pathogen or drug interven-
tion. Taken together, in vivo imaging can be used to evaluate
countermeasures against BSL3/4 threat agents to answer
these three fundamental questions and to develop counter-
measures under the U.S. FDA Animal Rule provision with
higher conﬁdence of clinical success and beneﬁt.
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